In February 2026, a group of European life sciences investors, research institutions, and ecosystem partners launched the European Life Sciences Coalition (ELSC) in association with Invest Europe, aiming to strengthen Europe’s life sciences and biotech venture ecosystem by mobilising additional investment.
The coalition brings together managers representing around €25bn in...
Agilent Technologies, a NYSE-listed biotech company, is to acquire US-based Biocare Medical, a global clinical pathology company, from an investor group led by Excellere Partners and GHO Capital Partners, in an all-cash transaction valued at US$950m.
“The acquisition of Biocare enhances Agilent’s pathology portfolio,” said Agilent President and CEO Padraig McDonnell.
Biocare is a high-growth global pathology specialist in immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH) solutions designed to improve patient health outcomes across oncology and broader clinical pathology. Biocare, which has more than 300 specialised...
